ATE528396T1 - Look-through-mutagenese zur entwicklung veränderter polypeptide mit verbesserten eigenschaften - Google Patents

Look-through-mutagenese zur entwicklung veränderter polypeptide mit verbesserten eigenschaften

Info

Publication number
ATE528396T1
ATE528396T1 AT05809866T AT05809866T ATE528396T1 AT E528396 T1 ATE528396 T1 AT E528396T1 AT 05809866 T AT05809866 T AT 05809866T AT 05809866 T AT05809866 T AT 05809866T AT E528396 T1 ATE528396 T1 AT E528396T1
Authority
AT
Austria
Prior art keywords
polypeptide
amino acids
mutagenesis
libraries
look
Prior art date
Application number
AT05809866T
Other languages
English (en)
Inventor
Roberto Crea
Original Assignee
Bioren Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioren Inc filed Critical Bioren Inc
Application granted granted Critical
Publication of ATE528396T1 publication Critical patent/ATE528396T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
AT05809866T 2004-07-06 2005-07-06 Look-through-mutagenese zur entwicklung veränderter polypeptide mit verbesserten eigenschaften ATE528396T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58591804P 2004-07-06 2004-07-06
PCT/US2005/024140 WO2006023144A2 (en) 2004-07-06 2005-07-06 Look-through mutagenesis for developing altered polypeptides with enhanced properties

Publications (1)

Publication Number Publication Date
ATE528396T1 true ATE528396T1 (de) 2011-10-15

Family

ID=35968026

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05809866T ATE528396T1 (de) 2004-07-06 2005-07-06 Look-through-mutagenese zur entwicklung veränderter polypeptide mit verbesserten eigenschaften

Country Status (9)

Country Link
US (1) US9012369B2 (de)
EP (1) EP1774019B1 (de)
JP (2) JP4939410B2 (de)
AT (1) ATE528396T1 (de)
BR (1) BRPI0513155B1 (de)
CA (1) CA2572917C (de)
ES (1) ES2372503T3 (de)
MX (1) MX2007000105A (de)
WO (1) WO2006023144A2 (de)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
EP2006381B1 (de) 2006-03-31 2016-02-03 Chugai Seiyaku Kabushiki Kaisha Verfahren zur kontrolle der blut-pharmakokinetik von antikörpern
WO2007127290A2 (en) * 2006-04-24 2007-11-08 Protelix, Inc. Method for producing viral vaccine and therapeutic peptide antigens
US8629244B2 (en) 2006-08-18 2014-01-14 Ablynx N.V. Interleukin-6 receptor binding polypeptides
EP2118281A2 (de) 2007-02-12 2009-11-18 Codexis, Inc. Struktur-wirkungs-beziehungen
EP2392653B1 (de) * 2007-07-12 2014-03-19 New England Biolabs, Inc. Restriktionsendonukleasen mit hoher Fidelität
EP4368721A2 (de) 2007-09-26 2024-05-15 Chugai Seiyaku Kabushiki Kaisha Verfahren zur modifizierung eines isoelektrischen punkts eines antikörpers durch aminosäuresubstitution in cdr
US9688762B2 (en) 2007-09-26 2017-06-27 Chugai Sciyaku Kabushiki Kaisha Modified antibody constant region
WO2009041621A1 (ja) * 2007-09-26 2009-04-02 Chugai Seiyaku Kabushiki Kaisha 抗il-6レセプター抗体
JP2011504740A (ja) 2007-11-27 2011-02-17 アブリンクス エン．ヴェー． ヘテロ二量体サイトカイン及び／又はこれらの受容体に指向性を有するアミノ酸配列、並びにこれを含むポリペプチド
US20110118447A1 (en) * 2007-12-31 2011-05-19 Xoma Technology Ltd. Methods and materials for targeted affinity enhancement
NO2708559T3 (de) 2008-04-11 2018-08-25
CN102076713B (zh) 2008-05-02 2015-03-25 诺华股份有限公司 改进的基于纤连蛋白的结合分子及其用途
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
EP2409991B1 (de) 2009-03-19 2017-05-03 Chugai Seiyaku Kabushiki Kaisha Variante einer konstanten antikörperregion
TWI646193B (zh) 2009-03-19 2019-01-01 中外製藥股份有限公司 抗體恆定區域改變體
WO2010111707A1 (en) 2009-03-27 2010-09-30 Sapphire Energy, Inc. Variant isoprenoid producing enzymes and uses thereof
CN105399828B (zh) 2009-04-10 2021-01-15 埃博灵克斯股份有限公司 用于治疗il-6r相关疾病和病症的改进的针对il-6r的氨基酸序列和包含其的多肽
US10618964B2 (en) 2009-04-10 2020-04-14 Ablynx N.V. Nanobody against IL-6R
NZ597314A (en) 2009-06-05 2013-07-26 Ablynx Nv Monovalent, bivalent and trivalent anti human respiratory syncytial virus (hrsv) nanobody constructs for the prevention and/or treatment of respiratory tract infections
US8518405B2 (en) * 2009-10-08 2013-08-27 The University Of North Carolina At Charlotte Tumor specific antibodies and uses therefor
WO2011051327A2 (en) 2009-10-30 2011-05-05 Novartis Ag Small antibody-like single chain proteins
WO2011051466A1 (en) 2009-11-02 2011-05-05 Novartis Ag Anti-idiotypic fibronectin-based binding molecules and uses thereof
WO2011064382A1 (en) 2009-11-30 2011-06-03 Ablynx N.V. Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
WO2011092233A1 (en) 2010-01-29 2011-08-04 Novartis Ag Yeast mating to produce high-affinity combinations of fibronectin-based binders
SG187225A1 (en) 2010-07-30 2013-02-28 Novartis Ag Fibronectin cradle molecules and libraries thereof
CN103339145A (zh) * 2010-09-22 2013-10-02 安姆根有限公司 运载体免疫球蛋白及其用途
US9845362B2 (en) 2010-10-08 2017-12-19 The University Of North Carolina At Charlotte Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same
AU2011337704B2 (en) 2010-11-30 2017-06-15 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
AU2012311443B2 (en) 2011-09-23 2016-12-01 Ablynx Nv Prolonged inhibition of interleukin-6 mediated signaling
BR112014008804A2 (pt) 2011-10-11 2017-06-13 Medimmune Llc suportes derivados de tn3 específicos para cd40l e métodos de uso dos mesmos
CN104080909A (zh) 2011-11-30 2014-10-01 中外制药株式会社 包含进入细胞内以形成免疫复合体的搬运体(载体)的药物
AU2013224851B2 (en) 2012-03-02 2018-03-01 Ablynx Nv Pseudomonas aeruginosa PcrV binding single variable domain antibodies
WO2014087010A1 (en) 2012-12-07 2014-06-12 Ablynx N.V. IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
EP2949789B1 (de) * 2013-01-24 2021-07-28 AbTLAS Co., Ltd. Auf einer proteinkombination basierende fv-bibliothek und herstellungsverfahren dafür
EP2989202B1 (de) 2013-04-25 2019-04-10 Sutro Biopharma, Inc. Die verwendung des lambda-gam proteins in der ribosomen-display-technologie
US20160069897A1 (en) * 2013-04-25 2016-03-10 Suthro Biopharma, Inc. Selection of fab fragments using ribosomal display technology
US10782290B2 (en) 2013-06-11 2020-09-22 National Center Of Neurology And Psychiatry Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (RRMS) patient, and method for determining applicability of novel therapy
PL3030682T3 (pl) 2013-08-05 2020-11-16 Twist Bioscience Corporation Biblioteki genowe syntezowane de novo
US11554181B2 (en) 2014-09-05 2023-01-17 The University Of North Carolina At Charlotte Tumor specific antibody conjugates and uses therefor
JP2017534617A (ja) 2014-10-21 2017-11-24 アブリンクス エン．ヴェー． Ｉｌ−６ｒ関連疾患の処置
WO2016126882A1 (en) 2015-02-04 2016-08-11 Twist Bioscience Corporation Methods and devices for de novo oligonucleic acid assembly
PL3263132T3 (pl) 2015-02-27 2024-04-15 Chugai Seiyaku Kabushiki Kaisha Kompozycja do leczenia chorób związanych z il-6
KR20240093725A (ko) 2015-03-12 2024-06-24 메디뮨 엘엘씨 알부민 융합 단백질의 정제 방법
WO2016172377A1 (en) 2015-04-21 2016-10-27 Twist Bioscience Corporation Devices and methods for oligonucleic acid library synthesis
JP6875683B2 (ja) 2015-05-19 2021-05-26 国立研究開発法人国立精神・神経医療研究センター 多発性硬化症（ｍｓ）患者の新規治療適用判断方法
JP6867302B2 (ja) 2015-05-21 2021-04-28 フル スペクトラム ジェネティクス， インコーポレイテッド タンパク質の特徴を改善する方法
KR20180050411A (ko) * 2015-09-18 2018-05-14 트위스트 바이오사이언스 코포레이션 올리고핵산 변이체 라이브러리 및 그의 합성
US11512347B2 (en) 2015-09-22 2022-11-29 Twist Bioscience Corporation Flexible substrates for nucleic acid synthesis
CN115920796A (zh) 2015-12-01 2023-04-07 特韦斯特生物科学公司 功能化表面及其制备
USD782516S1 (en) 2016-01-19 2017-03-28 Apple Inc. Display screen or portion thereof with graphical user interface
AU2017315294B2 (en) 2016-08-22 2023-12-21 Twist Bioscience Corporation De novo synthesized nucleic acid libraries
JP6871364B2 (ja) 2016-09-21 2021-05-12 ツイスト バイオサイエンス コーポレーション 核酸に基づくデータ保存
US10907274B2 (en) 2016-12-16 2021-02-02 Twist Bioscience Corporation Variant libraries of the immunological synapse and synthesis thereof
JP2020508661A (ja) 2017-02-22 2020-03-26 ツイスト バイオサイエンス コーポレーション 核酸ベースのデータ保存
WO2018170169A1 (en) 2017-03-15 2018-09-20 Twist Bioscience Corporation Variant libraries of the immunological synapse and synthesis thereof
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
KR102628876B1 (ko) 2017-06-12 2024-01-23 트위스트 바이오사이언스 코포레이션 심리스 핵산 어셈블리를 위한 방법
WO2018231864A1 (en) 2017-06-12 2018-12-20 Twist Bioscience Corporation Methods for seamless nucleic acid assembly
KR20200047706A (ko) 2017-09-11 2020-05-07 트위스트 바이오사이언스 코포레이션 Gpcr 결합 단백질 및 이의 합성 방법
KR20200074160A (ko) 2017-10-20 2020-06-24 가꼬우호우징 효고 이카다이가쿠 항il-6 수용체 항체를 함유하는 수술 후의 유착을 억제하기 위한 의약 조성물
CN111565834B (zh) 2017-10-20 2022-08-26 特韦斯特生物科学公司 用于多核苷酸合成的加热的纳米孔
CA3088911A1 (en) 2018-01-04 2019-07-11 Twist Bioscience Corporation Dna-based storage device and method for synthesizing polynucleotides using the device
AU2019270243A1 (en) 2018-05-18 2021-01-07 Twist Bioscience Corporation Polynucleotides, reagents, and methods for nucleic acid hybridization
AU2020229349A1 (en) 2019-02-26 2021-10-14 Twist Bioscience Corporation Variant nucleic acid libraries for GLP1 receptor
CA3131691A1 (en) 2019-02-26 2020-09-03 Twist Bioscience Corporation Variant nucleic acid libraries for antibody optimization
AU2020298294A1 (en) 2019-06-21 2022-02-17 Twist Bioscience Corporation Barcode-based nucleic acid sequence assembly
WO2021061829A1 (en) 2019-09-23 2021-04-01 Twist Bioscience Corporation Variant nucleic acid libraries for crth2

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2079802C (en) * 1990-04-05 2001-09-18 Roberto Crea Walk-through mutagenesis
AU1456101A (en) 1999-11-03 2001-05-14 Maxygen, Inc. Antibody diversity generation
JP2003516755A (ja) * 1999-12-15 2003-05-20 ジェネンテック・インコーポレーテッド ショットガン走査、すなわち機能性タンパク質エピトープをマッピングするための組み合わせ方法
US7647184B2 (en) * 2001-08-27 2010-01-12 Hanall Pharmaceuticals, Co. Ltd High throughput directed evolution by rational mutagenesis
US20040033569A1 (en) 2002-04-17 2004-02-19 Roberto Crea "Doping" in walk-through mutagenesis
CA2482863A1 (en) 2002-04-17 2003-10-30 Roberto Crea Universal libraries for immunoglobulins
ES2609102T3 (es) * 2003-06-27 2017-04-18 Bioren, LLC Mutagénesis por revisión

Also Published As

Publication number Publication date
BRPI0513155A (pt) 2008-04-29
WO2006023144A2 (en) 2006-03-02
US9012369B2 (en) 2015-04-21
CA2572917A1 (en) 2006-03-02
EP1774019A4 (de) 2009-05-20
JP4939410B2 (ja) 2012-05-23
JP2008505642A (ja) 2008-02-28
MX2007000105A (es) 2007-07-18
JP2012041347A (ja) 2012-03-01
EP1774019B1 (de) 2011-10-12
CA2572917C (en) 2012-04-03
BRPI0513155B1 (pt) 2021-07-20
WO2006023144A3 (en) 2006-08-17
EP1774019A2 (de) 2007-04-18
ES2372503T3 (es) 2012-01-20
US20080214406A1 (en) 2008-09-04

Similar Documents

Publication Publication Date Title
ATE528396T1 (de) Look-through-mutagenese zur entwicklung veränderter polypeptide mit verbesserten eigenschaften
WO2005003345A3 (en) Look-through mutagenesis
ES2078518T3 (es) Mutagenesis por desplazamiento completo.
Tu et al. Sequence analysis and molecular docking of antithrombotic peptides from casein hydrolysate by trypsin digestion
Camporeale et al. K8 and K12 are biotinylated in human histone H4
Jirácek et al. Development of Highly Potent and Selective Phosphinic Peptide Inhibitors of Zinc Endopeptidase 24-15 Using Combinatorial Chemistry (∗)
Schroeter et al. Bone protein “extractomics”: comparing the efficiency of bone protein extractions of Gallus gallus in tandem mass spectrometry, with an eye towards paleoproteomics
WO2003099999A3 (en) Generation and selection of protein library in silico
ATE344456T1 (de) Durch affinität ausgewählte unterschriftspeptide zur identifizierung und quantifizierung von proteinen
ATE437364T1 (de) Detektion von peptiden
CN105277712B (zh) 一种鉴定赖氨酸ε‑氨基侧链单甲基化修饰的方法
WO2002042427A3 (en) Mass tags for quantitative analysis
Slagboom et al. Analytical strategies in venomics
DE60109490D1 (de) Umgekehrtes labelierungsverfahren zur schnellen identifikation von marker/ziel-proteinen
JP2019507341A5 (de)
Fu et al. rMCP-2, the major rat mucosal mast cell protease, an analysis of its extended cleavage specificity and its potential role in regulating intestinal permeability by the cleavage of cell adhesion and junction proteins
DE69114339D1 (de) Verfahren zur Identifizierung oder Bestimmung von Proteinen und Verwendungen dazu.
DE69902924D1 (de) Neue methoden zum auffinden von liganden- und ziel-biomolekülen
ATE288589T1 (de) Verfahren zur analyse von proteinen
SE0302559D0 (sv) Method
Jurgilas et al. PO41, a snake venom metalloproteinase inhibitor isolated from Philander opossum serum
WO2008142664A3 (en) Exposed thymidine kinase 1 peptides, ligands and methods employing the same
Tong et al. Tandem immunoprecipitation of phosphotyrosine-mass spectrometry (TIPY-MS) indicates C19ORF19 becomes tyrosine-phosphorylated and associated with activated epidermal growth factor receptor
WO2006086288A3 (en) Methods for reducing the symptoms of autoimmunity and inflammation using binding proteins against antigens exposed on dead or dying cells
Jiang et al. Investigating the loss of major yolk proteins during the processing of sea cucumber (Apostichopus japonicus) using an MRM-based targeted proteomics strategy

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties